| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status | 
|---|---|---|---|---|---|---|---|---|---|---|---|
| 66302-0014-01 | 66302-0014 | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | Intravenous | Mar 10, 2015 | In Use | |
| 42747-0761-01 | 42747-0761 | mogamulizumab-kpkc | POTELIGEO | 4.0 mg/mL | Immunotherapy | Monoclonal Antibody | CCR4 | Intravenous | Aug 8, 2018 | In Use | |
| 59651-0342-01 | 59651-0342 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 60219-1714-02 | 60219-1714 | Lenalidomide | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 12, 2025 | In Use | |
| 43598-0514-01 | 43598-0514 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 64116-0011-12 | 64116-0011 | Interferon gamma-1b | Actimmune | Immunotherapy | Cytokine | Interferon | Feb 25, 1999 | Mar 31, 2015 | No Longer Used | ||
| 76282-0700-47 | 76282-0700 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 10, 2024 | In Use | |
| 55513-0956-01 | 55513-0956 | Panitumumab | Vectibix | 400.0 mg/20mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | In Use | |
| 70771-1677-01 | 70771-1677 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
| 70710-1033-01 | 70710-1033 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
| 42238-0111-12 | 42238-0111 | Interferon gamma-1b | Actimmune | 100.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Dec 1, 2013 | Jan 17, 2018 | No Longer Used | 
| 65483-0116-07 | 65483-0116 | Aldesleukin | Proleukin | 1.1 mg/mL | Immunotherapy | Cytokine | Interleukin-2 | Intravenous | May 5, 1992 | In Use | |
| 59572-0415-00 | 59572-0415 | Lenalidomide | Revlimid | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jul 7, 2006 | In Use | |
| 00078-0669-84 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | Feb 1, 2016 | In Use | 
| 61314-0240-63 | 61314-0240 | Denosumab | JUBBONTI | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 00003-4522-11 | 00003-4522 | Elotuzumab | Empliciti | 400.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov 30, 2015 | In Use | |
| 59572-0503-00 | 59572-0503 | Pomalidomide | Pomalyst | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 73536-0500-01 | 73536-0500 | ROPEGINTERFERON ALFA-2B | BESREMi | 500.0 ug/mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Nov 12, 2021 | In Use | |
| 67457-0991-15 | 67457-0991 | Trastuzumab | OGIVRI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov 29, 2019 | Feb 28, 2027 | In Use | 
| 70377-0052-11 | 70377-0052 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
| 82143-0002-01 | 82143-0002 | Bevacizumab-tnjn | Avzivi | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 1, 2025 | In Use | |
| 00085-1388-02 | 00085-1388 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Jan 13, 2016 | No Longer Used | ||
| 00173-0896-01 | 00173-0896 | Belantamab | Blenrep | 50.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | BCMA | Intravenous | Aug 5, 2020 | Jun 30, 2024 | No Longer Used | 
| 47781-0487-77 | 47781-0487 | Lenalidomide | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 00173-0808-01 | 00173-0808 | Ofatumumab | Arzerra | Immunotherapy | Monoclonal Antibody | CD20 | Oct 26, 2009 | Mar 31, 2012 | No Longer Used | 
Found 11765 results — Export these results
 Home